Why Journalists Won’t Investigate the Trans Medical Industry -Gerald Posner (#15)
29 May 2025
With Gerald Posner
Global
Gerald Posner, a Pulitzer Prize finalist and veteran pharmaceutical investigator, applies to the gender medicine industry the same forensic scrutiny he brought to the opioid crisis. He examines how off-label prescribing, corporate incentives and institutional capture drove the expansion of youth medical transition while mainstream journalism looked the other way — a pattern whose contours are clearly visible in the Cass Review's findings about the UK's own clinical failures.
Gerald Posner has spent decades following pharmaceutical companies into the darker corners of modern medicine. As a former lawyer, Pulitzer Prize finalist and investigator of the opioid epidemic, he arrives at the gender medicine debate not as an ideological combatant but as someone trained to read financial incentives, identify institutional capture and ask who benefits when a clinical consensus forms faster than the evidence can support it. In this episode he turns that forensic lens on the trans medical industry — and finds a pattern he recognises. The business model is his starting point. Posner explains how puberty blockers and cross-sex hormones have been prescribed off-label to children and adolescents on a scale that has consistently outrun the available evidence. Off-label prescribing is a legal mechanism that allows drugs to be used for purposes regulators have not formally approved, and it has historically been exploited by pharmaceutical companies to expand markets without the costly, rigorous trials that approval would require. The Cass Review, published in April 2024 following the most comprehensive independent examination of gender medicine in the world, arrived at a strikingly parallel finding: that the evidence base for puberty blockers in gender dysphoria was of poor quality, that long-term outcomes were largely unknown, and that prescribing had expanded well ahead of what the available data could justify. Posner also examines WPATH — the World Professional Association for Transgender Health — whose standards of care have shaped clinical guidance in the UK and elsewhere. Leaked internal communications revealed members discussing the softening of age thresholds and evidence requirements under pressure that appeared ideological rather than scientific. Posner places this within a broader pattern he has documented in other fields: professional bodies whose formal independence is gradually colonised by advocacy, until the guidelines they produce reflect the interests of a movement rather than the conclusions of dispassionate review. The parallel to the opioid crisis is deliberate and detailed. Posner traces how pharmaceutical companies cultivated medical opinion, funded professional associations and exploited regulatory grey zones to expand markets for addictive drugs while inconvenient safety signals were minimised or suppressed. He argues that the structural conditions in gender medicine are recognisably similar: a treatment paradigm with significant commercial beneficiaries, a professional consensus partly constructed under industry influence, and a regulatory environment that allowed weak evidence to circulate unchallenged. The role of journalism in enabling that environment runs through the conversation. Posner describes editors unwilling to commission investigations that would, in any other context, be considered routine accountability reporting. The Cass Review itself noted that the clinical culture around gender medicine had become one in which professionals felt unable to voice concerns without risking their careers — a chilling effect that depended, in part, on the absence of external scrutiny. That scrutiny is what Posner argues investigative journalism exists to provide, and what it conspicuously failed to deliver. His account of how that failure happened — through a combination of ideological alignment, fear of social consequences and commercial pressure from advertisers and platforms — is among the most detailed available from someone who has watched the industry from the inside.
